Bioclinica buys Clinverse citing pharma demand for trial payment efficiency

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology

Bioclinica HQ
Bioclinica HQ
Bioclinica has bought payment tech firm Clinverse continuing its acquisition-based growth strategy.

Buying Research Triangle Park (RTP) Durham, North Carolina-based Clinverse – financial terms of which were not provided – has added a portfolio of automated clinical trial payment services to Bioclinica’s eHealthSolutions business.

The payment firm’s previous investors include Hatteras Venture Partners of Durham and New Jersey-based Edison Partners, which led by a $9.1m (€6.9m) round in August 2014​.

Clinverse’s approach is to automatically track tax and exchange rate changes and automate payments to clinical trial sites and study participants.

The firm partnered with OmniComm Systems in 2013​ to combine its Clinpay automated payment tool with the latter’s electronic data capture (EDC) offering.

Bioclinica has not said whether this partnership will be maintained post-acquisition.  

The takeover continues the strategy Bioclinica enacted recent years.

In 2014, Bioclinica bought Blueprint Clinical​, a tech firm whose software helps drugmakers develop risk-based monitoring plans. 

A year later it acquired retention services firm MediciGroup​ and in September it bought pharmacovigilance and regulatory tech firm Synowledge​. 

Automated payment

In 2013, the US Government introduced the Sunshine Act​ in a bid to make financial interactions during the drug development process more transparent.

Since August of that year, drug companies and their contractors have been required to record all details of all the financial interactions they make, including payments to study investigators.

The need to collect and store this information in an efficient manner fuelled the growth of tech companies with Clinverse and peers like Greenphire and CFS competing for control of the increasingly lucrative market.

Bioclinica’s acquisition of Clinverse leaves Greephire as the last of these three firms to be independent. CFS was bought by DrugDev in October 2013​.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more